Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
03/31/2025
03/31/2024
03/31/2023
03/31/2022
03/31/2021
Revenus
245
240
216
219
184
133
Croissance des revenus (H/H)
7%
11%
-1%
19%
38%
14%
Coût des ventes
92
88
81
85
75
46
Bénéfice brut
152
152
134
133
109
87
Vente, Général et Administration
100
98
90
87
88
64
Recherche et développement
20
19
19
20
15
10
Frais d'exploitation
137
134
130
130
104
74
Autres revenus (charges) non opérationnels
2
-1
2
1
2
-2
Bénéfice avant impôts
7
5
-275
0
3
2
Charge d'impôt sur le revenu
8
7
-21
-1
1
-1
Bénéfice net
-1
-1
-254
0
1
3
Croissance du bénéfice net
-100%
-100%
--
-100%
-67%
200%
Actions en circulation (diluées)
5.53
5.42
5.38
5.4
5.3
5.1
Variation des actions (H-H)
1%
1%
0%
2%
4%
16%
EPS (dilué)
-0.28
-0.36
-47.2
0.17
0.35
0.64
Croissance du EPS
-99%
-99%
-27,868%
-51%
-45%
106%
Flux de trésorerie libre
37
42
41
23
34
35
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
62.04%
63.33%
62.03%
60.73%
59.23%
65.41%
Marge opérationnelle
6.12%
7.08%
1.38%
1.36%
2.17%
9.02%
Marge bénéficiaire
-0.4%
-0.41%
-117.59%
0%
0.54%
2.25%
Marge du flux de trésorerie libre
15.1%
17.5%
18.98%
10.5%
18.47%
26.31%
EBITDA
31
33
24
25
29
29
Marge EBITDA
12.65%
13.75%
11.11%
11.41%
15.76%
21.8%
D&A pour le résultat opérationnel
16
16
21
22
25
17
EBIT
15
17
3
3
4
12
Marge EBIT
6.12%
7.08%
1.38%
1.36%
2.17%
9.02%
Taux d'imposition effectif
114.28%
140%
7.63%
0%
33.33%
-50%
Statistiques clés
Clôture préc.
$88.57
Prix d'ouverture
$90.29
Plage de la journée
$88.85 - $91.9
Plage de 52 semaines
$55.45 - $152.03
Volume
37.0K
Volume moyen
114.2K
BPA (TTM)
0.65
Rendement en dividend
0.74%
Capitalisation boursière
$500.0M
Qu’est-ce que MLAB ?
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. The company is headquartered in Lakewood, Colorado and currently employs 730 full-time employees. The firm's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.